Raptiva Manufacturing Issues Will Not Delay Approval, Launch – Genentech
Executive Summary
Genentech expects the Raptiva manufacturing process to be ready in time for the biologic's late October user fee date, the company told investors Sept. 9
You may also be interested in...
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive
Raptiva Labeling Should Require Monitoring For Thrombocytopenia – Cmte.
Genentech/Xoma Raptiva labeling should require platelet count monitoring to minimize the risk of thrombocytopenia, FDA Dermatologic & Ophthalmic Drugs Advisory Committee recommended